Researchers at Eindhoven University of Technology (TU/e) in the Netherlands said the method works in a similar manner as a security system that opens the door depending on the person standing in front of it.
If the camera recognises the person, the door unlocks, but if the person is unknown, the door remains locked.
"Research into diagnostic tests tends to focus on the 'recognition', but what is special about this system is that it can think and that it can be connected to actuation such as drug delivery," said Maarten Merkx, professor at TU/e.
DNA is best known as a carrier of genetic information, but DNA molecules are also highly suitable for performing molecular calculations.
The sequence within a DNA molecule determines with which other DNA molecules it can react, which allows a researcher to programme desired reaction circuits.
To date biomedical applications of DNA computers have been limited because the input of DNA computers typically consists of other DNA and RNA molecules.
To determine whether someone has a particular disease, it is essential to measure the concentration of specific antibodies - agents that our immune system produces when we are ill.
Their method translates the presence of each antibody into a unique piece of DNA whereby the DNA computer can decide on the basis of the presence of one or more antibodies whether drug delivery, for example, is necessary.
"The presence of a particular DNA molecule sets in motion a series of reactions whereby we can get the DNA computer to run various programs," said Wouter Engelen from TU/e.
"Our results show that we can use the DNA computer to control the activity of enzymes, but we think it should also be possible to control the activity of a therapeutic antibody," said Engelen.
One of the potential applications of this system is to measure the quantity of therapeutic antibodies in the blood and decide whether it is necessary to administer any extra medication.
"By directly linking the measurement of antibodies to the treatment of the disease, we may be able to prevent side-effects and reduce costs in the future," said Merkx.
The study was published in the journal Nature Communications.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
